Fluid Biopsy Market to Grow with a CAGR of 11.50% through 2030

Rising Global Cancer Incidence and Advancements in Molecular Diagnostics and Genomic Technologies are expected to drive the Global Fluid Biopsy Market in the forecast period 2026-2030

According to TechSci Research report, “Fluid Biopsy Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2030F”, the Global Fluid Biopsy Market stood at USD 11.80 Billion  in 2024 and is anticipated to grow with a CAGR of 11.50% in the forecast period, 2026-2030.

Traditional diagnostic methods, such as tissue biopsies, are often associated with invasiveness, patient discomfort, and procedural risks. In contrast, fluid biopsies offer a non-invasive, safe, and repeatable alternative, providing clinicians with real-time insights into disease progression and treatment efficacy. This patient-centric approach has gained significant traction within clinical settings, fostering rapid market adoption. As healthcare systems globally shift towards personalized medicine, fluid biopsies are central to this transformation. They enable real-time molecular profiling, which aids in selecting targeted therapies, monitoring treatment responses, and identifying treatment resistance, particularly in oncology. These factors have amplified the demand for fluid biopsy solutions.

The regulatory environment for liquid biopsy technologies has become increasingly favorable, with key bodies like the FDA and EMA offering regulatory approvals and fast-track designations to several liquid biopsy tests. This regulatory backing has accelerated their adoption across clinical settings. In tandem, expanded reimbursement coverage for liquid biopsy tests has significantly lowered financial barriers for both healthcare providers and patients, facilitating wider adoption and supporting the market's growth.

Emerging markets, particularly in regions like Asia-Pacific and Latin America, are experiencing significant improvements in healthcare infrastructure and growing awareness of advanced diagnostic technologies. Government initiatives aimed at early cancer detection and the rising prevalence of chronic diseases are driving demand for cost-effective, minimally invasive solutions. Fluid biopsy technologies have emerged as an attractive alternative, aligning with the healthcare needs and economic considerations in these regions. The fluid biopsy market is witnessing substantial investment from venture capital, alongside strategic partnerships and mergers and acquisitions (M&A). These investments are accelerating the development, clinical validation, and commercialization of fluid biopsy technologies. Collaborations between diagnostics companies and pharmaceutical firms are also supporting the creation of companion diagnostics, broadening the clinical utility of these tests and enhancing their application in precision medicine.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Fluid Biopsy Market”

The Global Fluid Biopsy Market is segmented into indication, type, regional distribution, and company.

Based on its type, circulating tumor DNA (ctDNA) segment dominated the Global Fluid Biopsy Market. ctDNA is a fragment of tumor DNA that is released into the bloodstream as a result of tumor cell death. This biomarker is highly specific to cancer, making it an effective tool for early cancer detection, monitoring treatment efficacy, and tracking disease recurrence. The ability to detect even minute amounts of ctDNA in blood samples enhances the sensitivity and specificity of the diagnostic process, allowing for the identification of genetic mutations, tumor-specific alterations, and resistance markers. This precision has driven the clinical shift toward ctDNA as the preferred liquid biopsy option in oncology.

Unlike traditional tissue biopsies, which are invasive and associated with procedural risks and patient discomfort, ctDNA analysis is non-invasive, requiring only a blood sample. This repeatability is particularly advantageous for longitudinal monitoring, as patients can undergo regular testing without the need for additional invasive procedures. This non-invasive nature has led to wider acceptance of ctDNA-based fluid biopsy tests across various clinical settings, contributing to its growing market share. ctDNA plays a pivotal role in personalized medicine, as it enables the molecular profiling of tumors in real time. By analyzing ctDNA, clinicians can identify genetic mutations that drive cancer progression, allowing for the selection of targeted therapies tailored to the specific molecular characteristics of a patient's tumor. Additionally, ctDNA testing provides insight into the development of treatment resistance, which is crucial for adapting therapy regimens and optimizing treatment outcomes. As the focus on precision medicine intensifies globally, the demand for ctDNA-based liquid biopsies is expected to continue to rise, further solidifying its position as the dominant segment in the market.

Based on region, The Asia-Pacific (APAC) region is set to experience the fastest growth in the Global Fluid Biopsy Market, driven by several key factors that position the region at the forefront of diagnostic innovation, healthcare infrastructure improvements, and a rising demand for advanced medical technologies.The APAC region is witnessing significant advancements in healthcare infrastructure, with many countries investing heavily in upgrading their healthcare systems. This includes the integration of cutting-edge diagnostic technologies like fluid biopsy, which offer non-invasive, cost-effective, and real-time insights into disease progression, particularly in cancer. The rising healthcare standards across China, India, and Southeast Asia are making advanced diagnostics more accessible, particularly in urban areas and emerging markets. As the healthcare landscape continues to evolve, fluid biopsy solutions will become an integral part of clinical practices in these growing healthcare systems. Asia-Pacific is home to over half of the world’s population, and with the region’s aging population and the rising prevalence of chronic diseases—especially cancer—there is a significant push toward early detection and personalized treatment. In countries like China and India, cancer incidence rates are increasing rapidly due to lifestyle changes, urbanization, and aging demographics. As healthcare systems in these countries move towards personalized medicine, fluid biopsy technologies, especially those targeting circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), offer an attractive, scalable solution for early cancer detection and real-time monitoring. This is driving high demand for non-invasive diagnostic methods that can provide accurate results while reducing the overall burden on healthcare systems.

Major companies operating in Global Fluid Biopsy Market are:

• Bio-Rad Laboratories
• Guardant Health Inc.
• Illumina, Inc.
• Qiagen NV
• Laboratory Corporation of America Holdings
• F. Hoffmann-La Roche AG
• Thermo Fisher Scientific Inc.
• Johnson & Johnso
• Biocept Inc.
• Bio-Rad Laboratories, Inc.

Download Free Sample Report

Customers can also request for 10% free customization on this report.

“The demand for less invasive and patient-friendly diagnostic methods is on the rise, with patients and healthcare providers seeking alternatives to traditional tissue biopsies that can be invasive and uncomfortable. The increasing incidence of diseases, especially cancer, emphasizes the need for early detection and real-time monitoring, which fluid biopsy techniques can provide propell the growth of global fluid biopsy market. Additionally, the paradigm shift towards personalized medicine has boosted the relevance of fluid biopsy, as it offers valuable molecular and genetic information for tailored treatment strategies and the patient advocacy and awareness initiatives have played a crucial role in advocating for broader accessibility to these innovative diagnostics which contributes to foster the demand for Global Fluid Biopsy Market in the forecast period” said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“Fluid Biopsy Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Indication (Lung Cancer, Breast Cancer, Colorectal Cancer, Other) By Type (Circulating Tumor Cells, Circulating Tumor DNA, Cell-free DNA), By Region & Competition, 2020-2030F”, has evaluated the future growth potential of Global Fluid Biopsy Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Fluid Biopsy Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: sales@techsciresearch.com

Website: www.techsciresearch.com